In comparison, a selective α1 receptor antagonist (prazosin) decreased the risk of cardiac arrhythmias by 83% and a tested α1A-blocker (WB 4101) limited the incidence of arrhythmias by 49% [33]. Here, SERPINA1 is linked to chronic obstructive pulmonary disease.